Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Goals. To reveal the clinical efficacy and safety of Asmanex in patients with moderate and severe bronchial asthma (BA), treated with inhaled and/or systemic glucocorticosteroids (GCS), depending on the severity and level of control. Methods. 40 patients (age 18 to 65 years) were treated with Asmanex with equivalent to prior therapy with inhaled corticosteroids (ICS) doses or in combination with systemic corticosteroids prior therapy (without increasing the dose of systemic corticosteroids) for 3 months. Efficacy was assessed before and after the treatment on a background of Asmanex treatment by the need of additional using of agonists of β 2-adrenoreceptors, severity of daytime and nighttime asthma symptoms, dynamics of spirometry parameters. The efficacy of Asmanex was compared with the original baseline therapy of other inhaled corticosteroids at equivalent doses using the new delivery system.

Full Text

Restricted Access

About the authors

T V Latysheva

Institute of Immunology

Moscow, Russia

E A Latysheva

Institute of Immunology

Moscow, Russia

O V Shubina

Institute of Immunology

Moscow, Russia


  1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998, v. 351, p. 1225-1232.
  2. Adams P.F., Marano M.A. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 1995, No. 10, р. 193.
  3. Eagan T.M., Brogger J.C., Eide G.E., Bakke P.S. The incidence of adult asthma: a review. Int. J. Tuberc Lung Dis. 2005, v. 9 (6), р. 603-612.
  4. Grundy J., Matthews S., Bateman B. et al. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J. Allergy Clin. Immunol. 2002, v. 110, p. 784-789.
  5. Variations in the prevalence of respiratory symptoms, self reported asthma attacks and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. 1996, v. 9, p. 687-695.
  6. Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. Учебник для студентов медицинских вузов. М., «Медицина». 2000, 320 с.
  7. Warner J.O., Kaliner M.A., Crisci C.D. et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Allergy Clin. Immunol. Int. YJ World Allergy Org. 2006, v. 18, p. 4-10.
  8. Bousquet J. Allergy as a global problem: think globally act globally. Allergy. 2000, v. 57, p. 661-662.
  9. Allergy: The Unmet Need. A Blueprint for Better Patient Care. A Report of the Royal College of Physicians Working Party on the Provision of Allergy Services in the UK. London: Royal College of Physicians. 2003.
  10. Johansson S.G.O., Bieber T., Dahl R. et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004, v. 113, p. 832-836.
  11. Балаболкин И.И., Тюменцева Е.С. Применение ингаляционных глюкокортикостероидов в лечении бронхиальной астмы у детей. Иммунопатология, аллергология, инфектология. 2001, № 3, с. 38-47.
  12. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 2000, No. 162, р. 2341-2351.
  13. Mitchel C., Jenkins C., Scicchitano R., Rubenfeld A., Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary pharmacology and Therapeutics 16. 2003, p. 299-306.
  14. Barnes P.J. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir. Med. 2001, v. 95 (suppl B), p. 12-16.
  15. American Academy of Allergy, Asthma and Immunology. Consultation and referral guidelines citing the evidence: how the allergist/immunologist can help. J. Allergy Clin. Immunol. 2006, v. 117 (suppl), p. 495-S523.
  16. European Union of Medical Specialists Allergy Training Syllabus. Allergology and Clinical Immunology Section and Board: 07.06.2003. Available at:
  17. Kaliner M.A., Del Giacco S., Crisci C.D. et al. Requirements for physician training in allergy: key clinical competencies appropriate for the care of patients with allergic or immunologic diseases provisional position statement of the World Allergy Organization. Allergy Clin. Immunol. Int. J. World Allergy Org. 2006, v. 18, p. 92-97.
  18. Malling H.J., Gayraud J., Papageorgiu Y. et al. Objectives of training and specialty training core curriculum in allergology and clinical immunology. Allergy. 2004, v. 59, p. 579-588.
  19. Латышева Е.А., Ильина Н.И., Курбачева О.М. Форадил комби — оптимальное решение для контроля симптомов бронхиальной астмы среднетяжелого течения. Рос. Аллергол. Журн. 2009, № 6, с. 61-67.
  20. Ведущие направления в диагностике и лечении бронхиальной астмы. Основные положения отчета группы экспертов EPR2. National Institute of Health. National Heart, Lung and Blood Institute. NIH publication 97. Перевод c англ. Под ред. А.Н. Цой. М., «Гранть», 1998.
  21. Суточникова О.А. Ингаляционные ГКС — наиболее эффективные и безопасные противовоспалительные препараты для лечения астмы. Рус. мед. журн. 1997, № 2, с. 11-22.
  22. Van Essen-Zandvliet E.E., Hughes M.D. et al. Effects of 22 months of treatment with inhaled cor-ticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am. Rev. Respir. Dis. 1992, v. 146, p. 547-554.
  23. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington, D.C.: National Heart, Lung, and Blood Institute, 1995. Publication no. 95-24.
  24. Jeffery P.K., Godfrey W., Adelroth E. et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am. Rev. Respir. Dis. 1992, v. 145, p. 890-899.
  25. Горячкина Л.А. Исследование GOAL: достижимы ли цели лечения, сформулированные в GINA? Аллергология. 2005, № 1, c. 40-46.
  26. Bowler S. Inhaled steroids in asthma. Should the dose be reduced? Aus. Fam. Physic. 2002, v. 31 (8), p. 746-748.
  27. Емельянов А.В., Тренделева Т.Е., Краснощекова О.И. и соавт. Терапевтические возможности применения высоких доз беклометазона дипропионата у больных бронхиальной астмой. Аллергология. 2002, № 1, с. 41-43.
  28. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New Developments. Am. J. Respir. Care Med. 1998, v. 157 (3), part 2 (Suppl.), p. 1-53.
  29. Molimard M., Raherison C., Lignot S. et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. Journal of Aerosol Medicine. 2003, v. 16, No. 3, р. 249-254.
  30. Nora Y.K. Chew, Hak-Kim Chan. In vitro aerosol performance and dose uniformity between the Foradile aerolizer and the Oxis Turbuhaler. Journal of Aerosol Medicine. 2001, v. 14, No. 4, р. 495-501.
  31. Цой А.Н. Параметры фармакокинетики современных ингаляционных глюкокортикостероидов. Пульмонология. 1999, № 2, с. 73.
  32. Синопальников А.И., Клячкина И.Л. Средства для доставки лекарств в дыхательные пути при бронхиальной астме. Русские медицинские вести. 2003, № 1, с. 15-21.
  33. Белевский А.С. Современная терапия бронхиальной астмы, шаг вперед. Астма и аллергия. 2013, № 1, с. 14-16.
  34. Bousquet J.Int. J. Clin. Pract. 2009, v. 63, No. 5, p. 806.
  35. Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011, v. 37, p. 1308-1331.



Abstract - 20

PDF (Russian) - 0


Article Metrics

Metrics Loading ...


Copyright (c) 2013 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies